RAD51D and ovarian carcinoma: Other mutations were uniquely enriched in HRD+ predicted cases of breast and ovarian cancers (BARD1, BRIP1, MRE11, RAD51D) and cancer cohorts outside breast and ovarian cancer (RAD51B), suggesting additional unique drivers of HRD that may be cancer-cohort specific.